Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0226Source: DataRank Database

Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells is a research paper published in Cancer Discovery (2020). On theSindex it has a DataRank of 0. It has been cited 101 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access101 citations

Download PDF

Cite:

Linked data & code

hpa

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 6.46)OA: bronzeTopics (37)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Christine K. Lee ORCID,Kensuke Tateishi ORCID,Fumi Higuchi ORCID,Megha Subramanian ORCID,Seamus Rafferty

Live enrichment

PubMed:32606138 PMC:PMC7642007 OpenAlex:https://openalex.org/W3039485233

NIH

Grant: R01CA227821

NIH

Grant: P50CA165962

NCI

Grant: K12CA090354

National Institutes of Health

Grant: 1R01CA227821-01

Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas

National Institutes of Health

Grant: 4P50CA165962-04

SPORE: Targeted Therapies for Glioma

National Institutes of Health

Grant: 2K12CA090354-21

Training Program in Nervous System Tumors

FWCI

6.46

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: Elsevier TDM

journalhttps://cancerdiscovery.aacrjournals.org/content/candisc/10/11/1672.full.pdf

publisherhttps://cancerdiscovery.aacrjournals.org/content/candisc/10/11/1672.full.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/10/11/1672/1816357/1672.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-20-0226

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32606138

Fields of Study

PARP inhibition in cancer therapyGlioma Diagnosis and TreatmentNeuroblastoma Research and Treatments03 medical and health sciences0302 clinical medicineAntineoplastic Agents, AlkylatingGlycoside HydrolasesHumansNADTumor Cells, Cultured

MeSH Terms

Glycoside HydrolasesHumansNADTumor Cells, CulturedAntineoplastic Agents, Alkylating

Keywords

NAD+ kinaseIsocitrate dehydrogenaseBiologyCancer researchIDH1Cancer cellSynthetic lethalityCancerContext (archaeology)CytotoxicityIDH2BiochemistryMutantEnzymeIn vitroGeneticsGeneGlycoside HydrolasesTumor Cells, CulturedHumansNADAntineoplastic Agents, Alkylating

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 10 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822743.v1figshare

Additional file 10 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822743figshare

Additional file 1 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822746.v1figshare

Additional file 1 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822746figshare

Additional file 2 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822749.v1figshare

Additional file 2 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822749figshare

Additional file 3 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822752.v1figshare

Additional file 3 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822752figshare

Additional file 4 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822755.v1figshare

Additional file 4 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822755figshare

Additional file 5 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822758.v1figshare

Additional file 5 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822758figshare

Additional file 6 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822761.v1figshare

Additional file 6 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822761figshare

Additional file 7 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822764.v1figshare

Additional file 7 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822764figshare

Additional file 8 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822767.v1figshare

Additional file 8 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822767figshare

Additional file 9 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822773.v1figshare

Additional file 9 of Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

10.6084/m9.figshare.16822773figshare